As a matter of fact, our findings suggest that, in the metastatic setting, patients with a diagnosis of a KIT/PDGFRA WT GIST, except for those with known therapeutic molecular targets (involving BRAF or NTRK or FGFR), should always be treated with imatinib because the event of a cryptic KIT mutation may occur. Here, PDGFRA is linked to gastrointestinal stromal tumor.